CD4 T cells and toxicity from immune checkpoint blockade
Immunological Reviews · 2023-09 · 318 (1) · 96-109
DOI: 10.1111/imr.13248 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 25.07.2023. Verfasst von Noah Earland und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Immune‐related toxicities, otherwise known as immune‐related adverse events (irAEs), occur in a substantial fraction of cancer patients treated with immune checkpoint inhibitors (ICIs). Ranging from asymptomatic to life‐threatening, ICI‐induced irAEs can result in hospital admission, high‐dose corticosteroid treatment, ICI discontinuation, and in some cases, death. A deeper understanding of the factors underpinning severe irAE development will be essential for improved irAE prediction and prevention, toward maximizing the benefits and safety profiles of ICIs. In recent work, we applied mass cytometry, single‐cell RNA sequencing, single‐cell V(D)J sequencing, bulk RNA sequencing, and bulk T‐cell receptor (TCR) sequencing to identify pretreatment determinants of severe irAE development in patients with advanced melanoma. Across 71 patients separated into three cohorts, we found that two baseline features in circulation—elevated activated CD4 effector memory T‐cell abundance and TCR diversity—are associated with severe irAE development, independent of the affected organ system within 3 months of ICI treatment initiation. Here, we provide an extended perspective on this work, synthesize and discuss related literature, and summarize practical considerations for clinical translation. Collectively, these findings lay a foundation for data‐driven and mechanistic insights into irAE development, with the potential to reduce ICI morbidity and mortality in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, USA.
- Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, Missouri, USA.
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California, USA.
- Yale School of Medicine, New Haven, Connecticut, USA.
- Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut, USA.
- Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA.
ORCID-Profile: Noah Earland, Wubing Zhang, Abul Usmani, Aishwarya Nene, David Y Chen, Mario Sznol, Ruth Halaban, Aadel A Chaudhuri, Aaron M Newman
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- Donald E. and Delia B. Baxter Foundation
- V Foundation for Cancer Research
- Virginia and D.K. Ludwig Fund for Cancer Research
- Melanoma Research Alliance
- National Cancer Institute
Zitieren
APA
Earland, N., Zhang, W., Usmani, A., Nene, A., Bacchiocchi, A., Chen, D. Y., Sznol, M., Halaban, R., Chaudhuri, A. A., & Newman, A. M. (2023). CD4 T cells and toxicity from immune checkpoint blockade. Immunological Reviews, 318(1), 96-109. https://doi.org/10.1111/imr.13248
Vancouver
Earland N, Zhang W, Usmani A, Nene A, Bacchiocchi A, Chen DY, et al. CD4 T cells and toxicity from immune checkpoint blockade. Immunological Reviews. 2023;318(1):96-109. doi:10.1111/imr.13248
BibTeX
@article{Earland2023,
author = {Earland, Noah and Zhang, Wubing and Usmani, Abul and Nene, Aishwarya and Bacchiocchi, Antonella and Chen, David Y and Sznol, Mario and Halaban, Ruth and Chaudhuri, Aadel A and Newman, Aaron M},
title = {CD4 T cells and toxicity from immune checkpoint blockade},
journal = {Immunological Reviews},
year = {2023},
volume = {318},
number = {1},
pages = {96--109},
doi = {10.1111/imr.13248}
}
EUVIMED